Close Menu

NEW YORK (GenomeWeb) — Invivoscribe announced today that it has submitted its LeukoStrat CDx FLT3 Mutation Assay to the US Food and Drug Administration as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.